Published in Ann Neurol on June 01, 1996
How citation distortions create unfounded authority: analysis of a citation network. BMJ (2009) 3.66
Detection and quantification of mitochondrial DNA deletions in individual cells by real-time PCR. Nucleic Acids Res (2002) 2.88
Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol (2010) 1.60
Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol (2008) 1.29
Renal involvement in mitochondrial cytopathies. Pediatr Nephrol (2011) 1.16
Mitochondrial DNA analysis: polymorphisms and pathogenicity. J Med Genet (1999) 1.12
Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr Opin Neurol (2010) 1.08
Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol (2010) 1.05
Sporadic inclusion body myositis: the genetic contributions to the pathogenesis. Orphanet J Rare Dis (2014) 0.95
Renal mitochondrial cytopathies. Int J Nephrol (2011) 0.88
In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med (2008) 0.86
Disorders of nuclear-mitochondrial intergenomic signalling. J Bioenerg Biomembr (1997) 0.85
Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. Mol Ther (2017) 0.85
Muscle carnitine acetyltransferase and carnitine deficiency in a case of mitochondrial encephalomyopathy. J Inherit Metab Dis (1999) 0.84
"Bartter-like" phenotype in Kearns-Sayre syndrome. Pediatr Nephrol (2005) 0.81
Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Res (2016) 0.81
ANT1 is reduced in sporadic inclusion body myositis. Neurol Sci (2012) 0.78
Ongoing developments in sporadic inclusion body myositis. Curr Rheumatol Rep (2014) 0.78
Novel large-range mitochondrial DNA deletions and fatal multisystemic disorder with prominent hepatopathy. Biochem Biophys Res Commun (2011) 0.78
Mitochondrial dysfunction in myofibrillar myopathy. Neuromuscul Disord (2016) 0.75
Multiple mtDNA deletions: clinical and molecular correlations. J Inherit Metab Dis (2000) 0.75
mtDNA single macrodeletions associated with myopathies: absence of haplogroup-related increased risk. J Inherit Metab Dis (2005) 0.75
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med (1999) 9.18
Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature (2000) 5.71
Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol (1984) 5.21
Mitochondrial DNA deletions in progressive external ophthalmoplegia and Kearns-Sayre syndrome. N Engl J Med (1989) 4.87
The survival motor neuron protein in spinal muscular atrophy. Hum Mol Genet (1997) 4.86
Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet (1997) 4.29
Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology (1988) 4.28
Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology (2006) 4.11
Mitochondrial myopathies. Ann Neurol (1985) 3.81
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
An autosomal dominant disorder with multiple deletions of mitochondrial DNA starting at the D-loop region. Nature (1989) 3.75
Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell (1988) 3.57
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
A direct repeat is a hotspot for large-scale deletion of human mitochondrial DNA. Science (1989) 3.02
Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell (1988) 2.94
Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol (2000) 2.87
Andersen's syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features. Ann Neurol (1994) 2.82
Inclusion body myositis and myopathies. Ann Neurol (1995) 2.68
IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block. Ann Neurol (1990) 2.67
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol (1990) 2.66
Primary lateral sclerosis. A clinical diagnosis reemerges. Arch Neurol (1988) 2.62
Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat Genet (1999) 2.59
Mutations in the tail domain of DYNC1H1 cause dominant spinal muscular atrophy. Neurology (2012) 2.56
Correlating phenotype and genotype in the periodic paralyses. Neurology (2004) 2.55
Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res (1998) 2.54
Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr (1997) 2.54
mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet (1991) 2.53
Identification of a mutation in the gene causing hyperkalemic periodic paralysis. Cell (1991) 2.48
MELAS: clinical features, biochemistry, and molecular genetics. Ann Neurol (1992) 2.48
The genetics and pathology of oxidative phosphorylation. Nat Rev Genet (2001) 2.48
The natural history of primary lateral sclerosis. Neurology (2006) 2.31
Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology (2011) 2.28
Recombination via flanking direct repeats is a major cause of large-scale deletions of human mitochondrial DNA. Nucleic Acids Res (1990) 2.28
Myasthenia gravis. Study of humoral immune mechanisms by passive transfer to mice. N Engl J Med (1977) 2.23
Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med (1986) 2.22
Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol (2001) 2.20
Cytochemistry and immunocytochemistry of mitochondria in tissue sections. Methods Enzymol (1996) 2.19
The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain (2005) 2.17
A novel cDNA detects homozygous microdeletions in greater than 50% of type I spinal muscular atrophy patients. Nat Genet (1995) 2.17
Distribution of wild-type and common deletion forms of mtDNA in normal and respiration-deficient muscle fibers from patients with mitochondrial myopathy. Hum Mol Genet (1994) 2.16
Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. CIDD Study Group. Neurology (1991) 2.16
Melas: an original case and clinical criteria for diagnosis. Neuromuscul Disord (1992) 2.15
Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell (1994) 2.15
Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology (1992) 2.14
Lysosomal glycogen storage disease with normal acid maltase. Neurology (1981) 2.13
Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology (2006) 2.11
Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet (1991) 2.10
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology (2004) 2.09
TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry (2008) 2.07
Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve (1981) 2.06
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology (1994) 2.00
Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve (1983) 1.99
Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord (2001) 1.97
Widespread tissue distribution of mitochondrial DNA deletions in Kearns-Sayre syndrome. Neurology (1990) 1.97
Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol (1994) 1.97
Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid. J Exp Med (1998) 1.96
The mitochondrial tRNA(Leu(UUR)) mutation in mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS): genetic, biochemical, and morphological correlations in skeletal muscle. Am J Hum Genet (1992) 1.94
Muscle carnitine palmityltransferase deficiency and myoglobinuria. Science (1973) 1.93
Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology (1992) 1.93
Imprinting of the Angelman syndrome gene, UBE3A, is restricted to brain. Nat Genet (1997) 1.92
Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain (2007) 1.91
Lumping or splitting? "Ophthalmoplegia-plus" or Kearns-Sayre syndrome? Ann Neurol (1977) 1.90
Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology (2005) 1.90
Myasthenia gravis: passive transfer from man to mouse. Science (1975) 1.90
Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology (1989) 1.90
Detection of "deleted" mitochondrial genomes in cytochrome-c oxidase-deficient muscle fibers of a patient with Kearns-Sayre syndrome. Proc Natl Acad Sci U S A (1989) 1.88
Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol (1989) 1.88
The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology (1990) 1.87
Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. Neurology (2011) 1.86